Hemorrhoids Market Report 2026

The hemorrhoids market size has grown strongly in recent years. It will grow from $2.93 billion in 2025 to $3.11 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to rising prevalence of sedentary lifestyles, increasing incidence of chronic constipation, higher awareness of anorectal disorders, expansion of outpatient treatment facilities, availability of multiple treatment options.

The hemorrhoids market size is expected to see strong growth in the next few years. It will grow to $3.96 billion in 2030 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to increasing aging population, rising focus on early diagnosis and treatment, growing demand for minimally invasive procedures, expansion of teleconsultation for anorectal care, increased availability of advanced treatment modalities. Major trends in the forecast period include increasing adoption of minimally invasive hemorrhoid treatments, rising demand for over-the-counter medications, growing use of non-surgical procedures, expansion of homecare-based management solutions, enhanced focus on patient comfort and recovery.

The rising healthcare expenditure is expected to drive the growth of the hemorrhoids market in the coming years. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, or governments on preventing, treating, and managing health conditions. This expenditure is increasing due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often involve higher costs, leading to greater overall spending in healthcare. Higher healthcare expenditure enhances access to treatment, preventive care, medications, and advanced procedures, improving the management and outcomes for hemorrhoids. For example, according to the Centers for Medicare & Medicaid Services, a US-based agency overseeing Medicare and Medicaid programs, U.S. healthcare expenditures rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per individual. Consequently, rising healthcare expenditure is contributing to the growth of the hemorrhoids market.

Major companies in the hemorrhoid market are introducing innovative surgical products, such as minimally invasive hemorrhoid treatments, to improve patient comfort, reduce recovery time, and achieve better clinical outcomes. Minimally invasive hemorrhoid treatments involve advanced medical procedures that minimize tissue damage, pain, and recovery time compared to traditional hemorrhoidectomy methods. For instance, in December 2023, Medical Fintech Innovations B.V., a Netherlands-based technology company, launched the HemWell GEN 2 device. This next-generation product features the Hemwellectomy procedure, a minimally invasive electrosurgical solution for hemorrhoids. The technique provides a less painful alternative to traditional hemorrhoidectomy, enabling faster recovery and a quicker return to daily activities.

In March 2024, Karo Healthcare AB, a Sweden-based healthcare company, acquired the OTC brand Proctosedyl, a hemorrhoid treatment, from Bayer AG for an undisclosed amount. This acquisition strengthens Karo Healthcare’s presence in the Italian market, expands its digestive health portfolio, and improves consumer access to trusted hemorrhoid treatments, enhancing its competitive position in the region. Bayer AG, based in Germany, is a pharmaceutical company specializing in the production of OTC drugs for various medical conditions.

Major companies operating in the hemorrhoids market are Johnson & Johnson, Bayer AG, Abbott Laboratories, Medtronic Plc, Takeda Pharmaceutical Company, Boston Scientific Corporation, Church & Dwight Co. Inc., Dr. Reddy’s Laboratories Ltd, Glenmark Pharmaceuticals, B. Braun Melsungen AG, Sebela Pharmaceuticals, Citius Pharmaceuticals, AMATO PHARMACEUTICAL PRODUCTS LTD, Surkon Medical Co. Ltd., Privi Medical, CONMED Corporation, Integra LifeSciences Corporation, Takeda Consumer Healthcare, Fresenius Kabi, Sanofi.

North America was the largest region in the hemorrhoids market in 2025. The regions covered in the hemorrhoids market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemorrhoids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hemorrhoids market by increasing costs of imported pharmaceutical ingredients, medical devices used in procedural treatments, and packaging materials for topical medications. Hospitals and clinics in North America and Europe are most affected due to reliance on imported formulations and devices, while Asia-Pacific faces pricing pressure on generic drug manufacturing. These tariffs are raising treatment costs and affecting procurement budgets. However, they are also encouraging local drug manufacturing, domestic sourcing of medical supplies, and expanded production of cost-effective treatment options.

The hemorrhoids market research report is one of a series of new reports that provides hemorrhoids market statistics, including hemorrhoids industry global market size, regional shares, competitors with a hemorrhoids market share, detailed hemorrhoids market segments, market trends and opportunities, and any further data you may need to thrive in the hemorrhoids industry. This hemorrhoids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hemorrhoids are swollen and inflamed veins in the rectum and anus, which can lead to discomfort, pain, itching, and bleeding. They often occur due to increased pressure from straining during bowel movements, pregnancy, or prolonged sitting.

The main types of hemorrhoids include internal, external, and mixed hemorrhoids. Internal hemorrhoids form inside the rectum and are typically painless because this area lacks pain-sensitive nerves. However, they can cause bleeding during bowel movements and may occasionally protrude outside the anus. Treatments for hemorrhoids encompass medications, minimally invasive procedures, and surgical interventions. Care is delivered in hospitals, clinics, ambulatory surgery centers (ASCs), and homecare settings, with distribution through hospital pharmacies, retail pharmacies, and online pharmacies.

The hemorrhoids market consists of revenues earned by entities by providing medical services such as digital rectal exams, anoscopy, rubber band ligation, sclerotherapy, and hemorrhoidectomy or stapled hemorrhoidopexy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemorrhoids market also includes sales of creams, ointments, gels, pain relievers, anti-inflammatory drugs, and pre-moistened pads or wipes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.